Trial Profile
Randomized Phase 2 study of Nintedanib and Pirfenidone versus Nintedanib following a clinically meaningful decline in forced vital capacity in patients with idiopathic pulmonary fibrosis administering pirfenidone
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2022
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- 03 Jun 2022 Status changed to discontinued, according to Results published in the Medicine.
- 03 Jun 2022 Results comparing efficacy and safety of nintedanib with or without pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) who experienced disease progression during previous pirfenidone therapy, published in the Medicine.
- 27 Oct 2018 Status changed from suspended to completed.